PharmaLundensis

Focus: PharmaLundensis is a Swedish biotechnology company specializing in chelation therapies for heavy metal poisoning with a focus on neurological applications. The company operates at a modest scale with a legacy portfolio of radiopharmaceutical diagnostics and early-stage development programs.

Neurology

Profile data last refreshed 8h ago · AI intelligence enriched 1w ago

Open Jobs

About PharmaLundensis

AI assessmentNot Hiring

No open roles listed right now. Follow PharmaLundensis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

MICROLITE

Not specified

LOE Approaching

Legacy diagnostic kit with loss-of-exclusivity imminent; limited revenue significance and subject to generic competition.

Help build intelligence for PharmaLundensis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on unmet medical needs in heavy metal detoxification and neurotoxicology, a niche with limited competition but genuine clinical demand.
Location in Lund, Sweden provides access to strong academic research infrastructure and life sciences ecosystem.
Early-stage biotech environment enables direct impact on drug development and scientific strategy.

Watch Out For

Portfolio dominated by legacy radiopharmaceutical diagnostics (Technetium, Iodine, Selenium products) with loss-of-exclusivity approaching—limited revenue runway and restructuring risk.
Minimal hiring activity (zero active job openings at time of data collection) signals either stalled growth, financial constraint, or operational stability at minimal scale.
Pre-clinical pipeline extremely thin: only 2 programs in Phase 1/2 and Phase 2, no Phase 3 assets, and no disclosed funding, financial metrics, or publication record to validate scientific credibility.

Generated by Claude from PharmaLundensis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.